Navigation Links
Orion Pharma Selects ChemDiv as A Partner in Drug Discovery Services
Date:11/30/2007

SAN DIEGO, Nov. 30 /PRNewswire/ -- ChemDiv, Inc. and Orion Pharma today announced that Orion has chosen ChemDiv as a discovery partner in small molecule therapeutics for Orion's priority targets.

Under the terms of the agreement, ChemDiv will deploy the Discovery outSource(TM) platform for Orion's discovery program, including the world's largest commercially available chemical library, proprietary rational design, assay development, and bioscreening. ChemDiv will screen rationally designed chemical libraries against Orion's proprietary targets, and Orion will select hit series for subsequent lead optimization. Financial terms and identity of drug targets were not disclosed. The agreement provides options for expanding the discovery partnership.

"I am very satisfied with the commitment and exchange of information in our joint effort. We have a good basis for success," said Dr. Ari Koivisto, Orion's contact person in the collaboration. "Our partnership with ChemDiv complements our in-house discovery effort in this particular project," stated Dr. Antti Haapalinna, Director of Nonclinical R&D, Orion Pharma, Orion Corporation.

"We are delighted to offer discovery services to Orion Pharma in this partnership. We are especially pleased with the constructive dialog with Orion R&D, based on our mutual understanding and shared goals. Based on ChemDiv's diligence and track record, we are confident of success and look forward to expansion of this collaboration in the near future," commented Nikolay Savchuk, President and CEO of ChemDiv, Inc.

About Orion Corporation

Orion Corporation (OMX: ORNAV, ORNBV) is one of the leading pharmaceutical companies in the northern Europe. Orion develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. Pharmaceuticals generate about 95% of the Group's net sales, of which proprietary patented pharmaceutical innovations contribute a consi
'/>"/>

SOURCE ChemDiv, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Orion ICG, LLC Announces Acquisition of Cumberland Therapy Services, Inc.
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... 700 smiling little faces this holiday that might not ... monetary donations was given to the various charities as ... incur through the year. Some of the charities chosen ... , Shrine's Children's Hospitals, Toys for Tots and Crisis ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
(Date:12/24/2014)... 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... litigation currently underway in Pennsylvania’s Philadelphia Court of Common ... 24, 2014, court documents indicate that 1,183 claims had ... who developed gynecomastia (male breast growth) and other complications ... indicates that this represents an increase of more than ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... when malignancy is found early , , FRIDAY, Feb. ... Bader Ginsburg will face tough challenges following her surgery ... , At this point, it,s not clear exactly what ... suggest pancreatic adenocarcinoma, which accounts for about 85 percent ...
... Is No Champion of Corporate Governance,TUCSON, Ariz., Feb. 6 ... ) today commented on the recent announcement that an ... CITY) together with other related persons, including Donald E. ... Avalon, intends to initiate a consent solicitation against the ...
... PARK, Calif., Feb. 6 ROXRO announced today ... accepted for review the New Drug,Application (NDA) for ... management of acute moderate to severe pain.,ROX-888 is ... (NSAID), designed to provide ambulatory patients with a,convenient, ...
... Nu Skin Enterprises, Inc. (NYSE: NUS ) today announced ... quarterly cash dividend to $0.115 per share. Annually, this would ... The increase begins in the first quarter and will be ... 27, 2009. "Because of our financial stability and strong cash flow, ...
... 35% over same period in Fiscal 2008 -, ... dollars unless otherwise noted),BELLEVILLE, ON, Feb. 6 /PRNewswire-FirstCall/ ... research-based, technology-driven Canadian biopharmaceutical company, today announced financial ... fiscal year, ending December 31, 2008. , "We ...
... students with an in-depth licensed practical nursing career resource center to ... today,s thriving nursing industry. , ... Seattle, Washington (PRWEB) ... Nursing Career Resource Center offers comprehensive career and education information ...
Cached Medicine News:Health News:Supreme Court Justice Ginsburg Faces Tough Battle Against Pancreatic Cancer 2Health News:Supreme Court Justice Ginsburg Faces Tough Battle Against Pancreatic Cancer 3Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 2Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 3Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 4Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 5Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 6Health News:Providence Service Corporation Comments on Consent Solicitation by Avalon Correctional Services, Inc. 7Health News:ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain 2Health News:ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain 3Health News:Nu Skin Enterprises Announces 5 Percent Increase in Quarterly Dividend 2Health News:Bioniche Reports Fiscal 2009 Second Quarter 2Health News:Bioniche Reports Fiscal 2009 Second Quarter 3Health News:Bioniche Reports Fiscal 2009 Second Quarter 4Health News:Bioniche Reports Fiscal 2009 Second Quarter 5Health News:Bioniche Reports Fiscal 2009 Second Quarter 6Health News:Bioniche Reports Fiscal 2009 Second Quarter 7Health News:Bioniche Reports Fiscal 2009 Second Quarter 8Health News:Bioniche Reports Fiscal 2009 Second Quarter 9Health News:Licensed Practical Nurse Career Resource Center Launches 2Health News:Licensed Practical Nurse Career Resource Center Launches 3
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Jan. 10, 2011 Ascension Orthopedics, Inc., a market ... a European patent for a PyroCarbon humeral head design ... Modular Shoulder System released in September 2010. ... of Ascension Orthopedics, commented, "I am very pleased our ...
... Inc. (Nasdaq: RDEA ) today announced that ... Bayer HealthCare AG (Bayer) under the terms of their ... Ardea,s mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer ... initiation of a Phase 2 clinical study evaluating BAY ...
Cached Medicine Technology:Ascension Orthopedics Granted Patent for PyroCarbon Humeral Head Design 2Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration 2Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration 3
... Managing diabetes requires making decisions about insulin ... exercise. These decisions are guided by data ... information, and by the patterns that can ... Care Providers when the data is presented ...
... The Worlds First Solid-State Three-Color ... chosen to purchase over 3,000 Lumenis ... a busy practice, the Novus Varia ... lasers into a single, compact system ...
... Solid-State Three-Color Photocoagulator.,Retinal physicians throughout the ... 3,000 Lumenis multi-color photocoagulators.,For the retinal ... Novus Varia integrates green, yellow, and ... compact system that supports your treatment ...
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Medicine Products: